PLASMA CELL MYELOMA

This study is testing a new COVID-19 vaccine called GEO-CM04S1 against standard mRNA vaccines in people with blood cancers who have received a stem cell transplant or cellular therapy. The goal is to see if the new vaccine creates a stronger immune response in these vulnerable pa…

This early-stage trial is testing whether adding specially treated immune cells, called 'veto cells,' can help patients with blood cancers or bone marrow disorders after a stem cell transplant from a half-matched donor. The goal is to help the donor's cells grow and work in the p…

This study is testing a new combination of four drugs for people newly diagnosed with multiple myeloma, a cancer of plasma cells. The goal is to find the safest and most effective dose and see how well the drugs work together to control the cancer. Researchers will closely monito…

This study is testing whether people with multiple myeloma who are in a deep, sustained remission can safely stop their maintenance therapy. Researchers want to see if active monitoring without ongoing treatment can keep the cancer in remission for at least one year. The goal is …

This study is testing if giving the drug daratumumab after a patient's own stem cell transplant helps control multiple myeloma for a longer time. It involves 31 patients who have had the transplant. The main goal is to see if this extra treatment can prevent the cancer from progr…

This study tests whether adding a targeted drug called belantamab mafodotin to standard lenalidomide treatment can eliminate tiny amounts of remaining cancer cells in multiple myeloma patients who have had a stem cell transplant. The goal is to help patients achieve and maintain …

This large, late-stage trial aims to find the best initial treatment and long-term management strategy for people newly diagnosed with a specific type of blood cancer called multiple myeloma. It compares two different three-drug combinations to see which one better controls the c…

This study is testing whether adding the immunotherapy drug elotuzumab to standard maintenance therapy (lenalidomide) helps keep multiple myeloma from returning after a patient's own stem cell transplant. The trial involves 113 patients who have recently undergone transplant for …

This early-stage study is testing whether immune cells from healthy donors, given along with two other drugs, are safe for people with advanced colorectal, stomach, or hard-to-treat blood cancers. The goal is to see if this combination helps the donor immune cells last longer in …

This study is testing whether adding a new drug called isatuximab to a standard two-drug combination can delay or prevent high-risk smoldering multiple myeloma from progressing to active, symptomatic disease. It will involve about 337 patients who have the high-risk early form of…

This study aims to understand why people who survive a blood cancer transplant have a higher risk of heart disease. Researchers will closely monitor 350 adult patients' heart, lung, and muscle function before their transplant and for two years after. The goal is to learn how thes…

This study is testing a special website designed to help young women recently diagnosed with cancer make decisions about preserving their fertility. Cancer treatments can sometimes affect a woman's ability to have children later, and this tool provides information to help them un…